• KOL
    • Myocardial Infarction
    • Erik Magnus Ohman
    • Erik Magnus Ohman: Influence Statistics

      Erik Magnus Ohman

      Erik Magnus Ohman

      Show email address

      Duke University Medical Center-Duke Clinical Research Institute, Durham, NC, USA. | Department of Cardiology‚ Hamilton Health Sciences, Canada (M.K., E.M.O.). | Duke ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Erik Magnus Ohman:Expert Impact

      Concepts for whichErik Magnus Ohmanhas direct influence:Myocardial infarction,Acute coronary syndromes,Acute coronary,Acute myocardial infarction,Cardiogenic shock,Thrombolytic therapy,Creatine kinase,Major bleeding.

      Erik Magnus Ohman:KOL impact

      Concepts related to the work of other authors for whichfor which Erik Magnus Ohman has influence:Myocardial infarction,Atrial fibrillation,Acute coronary syndrome,Cardiovascular disease,Heart failure,Cardiogenic shock,Coronary artery.

      KOL Resume for Erik Magnus Ohman

      Year
      2022

      Duke University Medical Center-Duke Clinical Research Institute, Durham, NC, USA.

      Department of Cardiology‚ Hamilton Health Sciences, Canada (M.K., E.M.O.).

      2021

      Duke University Medical Center-Duke Clinical Research Institute, Durham, NC 27710, USA.

      2020

      Department of Cardiology, Duke University Medical Center–Duke Clinical Research Institute, Durham, NC 27710, USA

      2019

      Duke Clinical Research Institute, Duke University School of Medicine, 200 Morris Street, 6318, Durham, NC, 27701, USA

      2018

      Department of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA.

      Duke Clinical Research Institute, Duke University Medical Center, Durham, NC

      2017

      Duke Clinical Research Institute, Duke University, Durham, NC, USA

      2016

      Duke Hospital, Duke Program for Advanced Coronary Disease, Durham, NC, United States

      2015

      From the Duke Clinical Research Institute, Durham, NC (K.K., S.A.H., Q.Y., P.J.S., C.M., E.M.O., P.T., J.H.A., L.K.N.); Cardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, New York University School of Medicine and NYU Langone Medical Center, New York, NY (J.S.H.); Department of Medicine, Stanford University, Stanford, CA (K.W.M., R.A.H.); Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY (D.J.M.); Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand (H.D.W.); Department of Medicine, University of Alberta, Edmonton, Canada (P.W.A.); Department of Cardiology, University Hospitals Leuven, Leuven, Belgium (F.V.d.W.); and Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (R.P.G.).

      Programme for Advanced Coronary Diseases, Division of Cardiovascular Medicine, Duke Heart Center, Ambulatory Care, Durham, USA

      Program for Advanced Coronary Disease, Duke Medicine, Durham, NC (M.O.)

      the Duke Clinical Research Institute, Durham, North Carolina

      Duke Clinical Research Institute, Durham, NC (R.H., D.W., J.H.A., P.T., R.D.L., E.M.O., M.T.R.)

      2014

      From the Hadassah-Hebrew University Medical Center, Jerusalem, Israel (D.P.); Icahn School of Medicine at Mount Sinai, New York, NY (R.M.); Cardiovascular Research Foundation, New York, NY (R.M., K.X., G.W.S.); Duke University Medical Center, Durham, NC (E.M.O.); Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand (H.D.W.); and Columbia University Medical Center, New York, NY (J.D.N., G.W.S.).

      Program for Advanced Coronary Disease, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina

      Division of Cardiology, Department of Medicine, Duke University School of Medicine and the Duke Clinical Research Institute, Duke University, Durham, NC, USA

      Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.

      2013

      Division of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina

      Medisch Centrum Alkmaar, Alkmaar, The Netherlands

      Heart Institute (InCor) - University of Sao Paulo Medical School, Sao Paulo, Brazil

      From the Duke Clinical Research Institute, Durham, NC.

      Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Erik Magnus Ohman is among the top experts in the world.
      Concept World rank
      median 1 minute #1
      thrombocytopenia hitt #1
      elevation ck #1
      intracoronary heparin #1
      perfecting #1
      major aim therapy #1
      nste acss #1
      implementation definition #1
      diabetes mellitus acs #1
      combination therapy cangrelor #1
      placebo p00014 #1
      nste acs #1
      death cardiac rehospitalization #1
      aortic counterpulsation #1
      early iabp #1
      mir3135b chronic hf #1
      hemodynamic support outcomes #1
      eptifibatide receptors #1
      blood sequencing reveals #1
      unstable blood #1
      phase xc001 #1
      nsteacs mir3135b #1
      patients prolonged dilatations #1
      angina unstable angioplasty #1
      scd nste acs #1
      95 ichs #1
      abciximab thrombolytic therapy #1
      patients chronic aspirin #1
      site iabp #1
      levels mir3135b #1
      pci ranolazine #1
      placebo kf #1
      pci inotropes #1
      cad catheterization #1
      scd cardiovascular deaths #1
      thrombosis prolonged heparin #1
      nonfatal stroke event #1
      timi creatine kinase #1
      thrombocytopenia independent predictor #1
      mcs implantation survival #1
      thrombocytopenia suspected hit #1
      gp iib treatment #1
      treated iabp #1
      p0001 timi #1
      counterpulsation complications #1
      treatment nste #1
      medication pci #1
      mb myoglobin #1
      balloon counterpulsation patients #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Erik Magnus Ohman

      KOL-Index: 20940

      OBJECTIVES: This study sought to develop a risk score predictive of bleeding in patients undergoing percutaneous coronary intervention (PCI) and to investigate the impact of bleeding on subsequent mortality.

      BACKGROUND: Bleeding complications after PCI have been independently associated with early and late mortality.

      METHODS: This study represents a patient-level pooled analysis including 17,034 patients undergoing PCI from 3 large, randomized trials of bivalirudin versus heparin plus ...

      Known for Harmonizing Outcomes | Subsequent Mortality | Acute Myocardial | Patients Pci | Bleeding Risk
      KOL-Index: 20249

      CONTEXT: The relationship of platelet function testing measurements with outcomes in patients with acute coronary syndromes (ACS) initially managed medically without revascularization is unknown.

      OBJECTIVE: To characterize the differences and evaluate clinical outcomes associated with platelet reactivity among patients with ACS treated with clopidogrel or prasugrel.

      DESIGN, SETTING, AND PATIENTS: Patients with medically managed unstable angina or non-ST-segment elevation myocardial ...

      Known for Prasugrel Clopidogrel | Platelet Function | Patients Acs | 30 Months | 75 Years
      KOL-Index: 19975

      BACKGROUND: The aim of this study was to assess anticoagulation with the direct thrombin inhibitor bivalirudin during percutaneous coronary intervention in individuals with moderate and high-risk acute coronary syndromes.

      METHODS: 13,819 individuals in the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial were prospectively randomly assigned to receive heparin (unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitors, bivalirudin plus glycoprotein ...

      Known for Glycoprotein Iib | Inhibitors Bivalirudin | Acute Catheterization | Coronary Intervention | Composite Ischaemia
      KOL-Index: 19803

      CONTEXT: At 30-day follow-up, patients with moderate- and high-risk acute coronary syndromes (ACS) undergoing early invasive treatment in the ACUITY trial with bivalirudin monotherapy vs heparin plus glycoprotein (GP) IIb/IIIa inhibitors had noninferior rates of adverse ischemic events with reduced rates of major bleeding. Deferred upstream use of GP IIb/IIIa inhibitors for selective administration to patients undergoing percutaneous coronary intervention (PCI) resulted in a significant ...

      Known for Acuity Trial | Gp Iib | Composite Ischemia | Antithrombotic Strategies | Iiia Inhibitors
      KOL-Index: 19421

      CONTEXT: Intra-aortic balloon counterpulsation (IABC) is an adjunct to revascularization in patients with cardiogenic shock and reduces infarct size when placed prior to reperfusion in animal models.

      OBJECTIVE: To determine if routine IABC placement prior to reperfusion in patients with anterior ST-segment elevation myocardial infarction (STEMI) without shock reduces myocardial infarct size.

      DESIGN, SETTING, AND PATIENTS: An open, multicenter, randomized controlled trial, the ...

      Known for Infarct Size | 95 Patients | Aortic Balloon | Anterior Myocardial | Primary Pci
      KOL-Index: 18477

      CONTEXT: Few data document current cardiovascular (CV) event rates in stable patients with atherothrombosis in a community setting. Differential event rates for patients with documented coronary artery disease (CAD), cerebrovascular disease (CVD), or peripheral arterial disease (PAD) or those at risk of these diseases have not been previously evaluated in a single international cohort.

      OBJECTIVE: To establish contemporary, international, 1-year CV event rates in outpatients with ...

      Known for Event Rates | Patients Risk Factors | Year Cardiovascular | Cad Pad | Risk Atherothrombosis
      KOL-Index: 18084

      OBJECTIVES: This study sought to determine if the efficacy of bivalirudin alone versus heparin plus a glycoprotein (GP) IIb/IIIa inhibitor is dependent upon the duration of clopidogrel pre-treatment in patients undergoing percutaneous coronary intervention (PCI) in the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

      BACKGROUND: The administration of a clopidogrel loading dose several hours before PCI reduces the risk of periprocedural thrombotic ...

      Known for Acute Coronary | Pci Bivalirudin | Clopidogrel Treatment | Gp Iib | Angioplasty Balloon
      KOL-Index: 17913

      BACKGROUND: Treatment with prasugrel and aspirin improves outcomes compared with clopidogrel and aspirin for patients with acute coronary syndrome who have had angiography and percutaneous coronary intervention; however, no clear benefit has been shown for patients managed first with drugs only. We assessed outcomes from the TRILOGY ACS trial based on whether or not patients had coronary angiography before treatment was chosen.

      METHODS: TRILOGY ACS (ClinicalTrials.gov number NCT00699998) ...

      Known for Myocardial Infarction | Trilogy Acs | Patients Angiography | Primary Endpoint | Prasugrel Clopidogrel
      KOL-Index: 17891

      BACKGROUND: Dual antiplatelet therapy in older versus younger patients with acute coronary syndromes is understudied. Low-dose prasugrel (5 mg/d) is recommended for younger, lower-body-weight patients and elderly patients with acute coronary syndromes to mitigate the bleeding risk of standard-dose prasugrel (10 mg/d).

      METHODS AND RESULTS: A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to ...

      Known for Acute Coronary Syndromes | Elderly Patients | Bleeding Risk | ≥75 Years | Reduceddose Prasugrel
      KOL-Index: 17589

      OBJECTIVES: The purpose of this study was to determine the predictors of major bleeding and the impact of major bleeding on outcomes, including mortality, in acute coronary syndromes (ACS).

      BACKGROUND: Whether major bleeding independently predicts mortality in patients with ACS undergoing an early invasive strategy is undefined.

      METHODS: Patients (n = 13,819) with moderate- and high-risk ACS were randomized to heparin (unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibition ...

      Known for Major Bleeding | Day Mortality | Patients Acs | Bivalirudin Monotherapy | Acuity Trial
      KOL-Index: 17483

      OBJECTIVES: This study sought to evaluate the impact of upstream clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) requiring coronary artery bypass grafting (CABG) from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

      BACKGROUND: Despite benefits of clopidogrel in patients with NSTE-ACS undergoing percutaneous coronary intervention, this agent is often not administered upstream (before angiography) as recommended by ...

      Known for Acute Coronary | Clopidogrel Administration | Artery Bypass | Patients Cabg | Syndromes Undergoing
      KOL-Index: 17459

      BACKGROUND: Despite the known association of diabetes mellitus with cardiovascular events, there are few contemporary data on the long-term outcomes from international cohorts of patients with diabetes mellitus. We sought to describe cardiovascular outcomes at 4 years and to identify predictors of these events in patients with diabetes mellitus.

      METHODS AND RESULTS: The Reduction of Atherothrombosis for Continued Health (REACH) registry is an international registry of patients at high ...

      Known for Diabetes Mellitus | Heart Failure | Cardiovascular Events | Patients Risk | Adjusted 95
      KOL-Index: 17107

      OBJECTIVES: This study was designed to determine the impact of bivalirudin on 1-year outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).

      BACKGROUND: The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial demonstrated that in moderate- and high-risk ACS patients undergoing PCI, bivalirudin alone compared to unfractionated heparin (UFH) or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor resulted in less ...

      Known for Acute Catheterization | Glycoprotein Iib | Coronary Intervention | Patients Pci | 1 Year
      KOL-Index: 17063

      CONTEXT: The American College of Cardiology/American Heart Association (ACC/AHA) guidelines for the management of non-ST-segment elevation acute coronary syndromes (NSTE ACS) recommend early invasive management for high-risk patients, given the benefits with this approach demonstrated in randomized clinical trials.

      OBJECTIVES: To determine the use and predictors of early invasive management strategies (cardiac catheterization <48 hours following presentation) in high-risk patients with ...

      Known for Early Invasive Management | Unstable Angioplasty | Nste Acs | Acc Aha | Highrisk Patients
      KOL-Index: 17051

      BACKGROUND: Current guidelines for patients with moderate- or high-risk acute coronary syndromes recommend an early invasive approach with concomitant antithrombotic therapy, including aspirin, clopidogrel, unfractionated or low-molecular-weight heparin, and glycoprotein IIb/IIIa inhibitors. We evaluated the role of thrombin-specific anticoagulation with bivalirudin in such patients.

      METHODS: We assigned 13,819 patients with acute coronary syndromes to one of three antithrombotic ...

      Known for Heparin Bivalirudin | Glycoprotein Iib | Unstable Angioplasty | Acute Coronary Syndromes | Rates Ischemia

      Key People For Myocardial Infarction

      Top KOLs in the world
      #1
      Braunwald Braunwald
      myocardial infarction heart failure atrial fibrillation
      #2
      Robert M Califf
      myocardial infarction thrombolytic therapy heart failure
      #3
      Frans J J Van de Werf
      myocardial infarction acute coronary thrombolytic therapy
      #4
      Eric J Topol
      myocardial infarction thrombolytic therapy coronary angioplasty
      #5
      Christian Wilhelm Hamm
      myocardial infarction aortic valve acute coronary syndromes
      #6
      Harlan M Krumholz
      heart failure united states acute myocardial infarction

      Duke University Medical Center-Duke Clinical Research Institute, Durham, NC, USA. | Department of Cardiology‚ Hamilton Health Sciences, Canada (M.K., E.M.O.). | Duke University Medical Center-Duke Clinical Research Institute, Durham, NC 27710, USA. |

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.